Diagnostic Approach for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Clinical Context and Diagnostic Considerations

The American Gastroenterological Association recommends liver biopsy as the gold standard for confirming cirrhosis and determining the underlying etiology in patients with metabolic risk factors and chronic liver injury, as it provides histologic confirmation of cirrhosis stage and guides management decisions 1, 3
The American Association for the Study of Liver Diseases suggests that metabolic risk factors, such as hypertension and diabetes, are core components of metabolic syndrome strongly associated with non-alcoholic steatohepatitis (NASH) 1, 2
A 10-year history of elevated aminotransferases indicates long-standing hepatocellular damage, and liver biopsy is necessary to establish the diagnosis definitively and guide decisions about liver transplant evaluation 2, 3

The European Association for the Study of the Liver recommends that laboratory assessment should include complete hepatic panel, complete blood count with platelets, viral hepatitis serologies, autoimmune markers, iron studies, and ceruloplasmin to exclude other treatable causes of chronic liver disease 2, 5, 8
Abdominal ultrasound with Doppler should be performed to confirm ascites, assess liver morphology, evaluate for hepatocellular carcinoma, and assess portal vein patency and direction of flow 6, 7
Diagnostic paracentesis should be performed to calculate serum-ascites albumin gradient, exclude spontaneous bacterial peritonitis, and rule out malignant ascites 3
Once cirrhosis is confirmed by biopsy, priorities include hepatocellular carcinoma surveillance, variceal screening, liver transplant evaluation, management of ascites, and metabolic optimization 1, 3

Non-invasive tests have reduced accuracy in the presence of ascites and portal hypertension, and should not be relied upon solely for diagnosis in decompensated disease 1, 3
Up to 15-20% of patients with metabolic risk factors and elevated aminotransferases have alternative or concurrent liver diseases, and autoimmune hepatitis, hemochromatosis, and Wilson's disease must be excluded 2, 8
Patients with ascites have decompensated cirrhosis and require urgent specialist referral for transplant evaluation, and hepatocellular carcinoma surveillance and variceal screening should be initiated immediately once cirrhosis is confirmed 3